Media stories about Perrigo (NYSE:PRGO) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Perrigo earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.2869001676076 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment’s analysis:
- SK Capital closes Perrigo API buy (pehub.com)
- Perrigo Co. Plc breached its 50 day moving average in a Bearish Manner : PRGO-US : November 21, 2017 (finance.yahoo.com)
- Zacks.com featured highlights: Boot Barn, Perrigo, Boise Cascade, DXC Technology and Koppers (finance.yahoo.com)
- Perrigo Company Completes Divestiture Of API Business For $110 Million (finance.yahoo.com)
- SK Capital Closes Acquisition of Perrigo’s API Business and Changes Name to Wavelength Pharmaceuticals (markets.financialcontent.com)
Perrigo (NYSE PRGO) traded down $0.69 during mid-day trading on Tuesday, reaching $85.20. The company had a trading volume of 968,500 shares, compared to its average volume of 1,737,415. The company has a market cap of $12,100.00, a PE ratio of 17.53, a PEG ratio of 1.83 and a beta of 0.59. Perrigo has a fifty-two week low of $63.68 and a fifty-two week high of $91.73. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.72 and a quick ratio of 1.24.
Perrigo (NYSE:PRGO) last released its quarterly earnings data on Thursday, November 9th. The company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.28. The business had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.17 billion. Perrigo had a positive return on equity of 11.60% and a negative net margin of 26.28%. The firm’s quarterly revenue was down 2.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.65 EPS. analysts predict that Perrigo will post 4.88 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 19th. Investors of record on Friday, December 1st will be given a $0.16 dividend. The ex-dividend date is Thursday, November 30th. This represents a $0.64 annualized dividend and a yield of 0.75%. Perrigo’s dividend payout ratio (DPR) is presently -6.99%.
A number of research analysts recently issued reports on the company. Canaccord Genuity restated a “buy” rating and set a $100.00 price target (up previously from $88.00) on shares of Perrigo in a report on Wednesday, September 13th. Royal Bank Of Canada reiterated a “sell” rating and set a $64.00 target price on shares of Perrigo in a report on Wednesday, September 13th. Deutsche Bank AG upped their target price on Perrigo from $88.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, September 14th. Wells Fargo & Company upped their target price on Perrigo to $90.00 and gave the stock a “market perform” rating in a report on Friday, November 10th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $107.00 target price on shares of Perrigo in a report on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $91.50.
TRADEMARK VIOLATION NOTICE: This story was originally posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.truebluetribune.com/2017/11/21/perrigo-prgo-getting-somewhat-positive-press-coverage-analysis-finds.html.
In other news, EVP Jeffrey Needham sold 3,595 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $89.49, for a total transaction of $321,716.55. Following the transaction, the executive vice president now directly owns 10,118 shares of the company’s stock, valued at approximately $905,459.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Sharon Kochan sold 318 shares of the stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $81.36, for a total value of $25,872.48. Following the transaction, the executive vice president now directly owns 10,231 shares in the company, valued at $832,394.16. The disclosure for this sale can be found here. Insiders have sold a total of 6,242 shares of company stock worth $532,091 over the last three months. Insiders own 6.90% of the company’s stock.
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Receive News & Ratings for Perrigo Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company and related companies with MarketBeat.com's FREE daily email newsletter.